全外显子组测序检测胶质瘤患者血浆游离DNA的研究
研究纳入2015年6月至2016年9月南通大学附属医院6例胶质瘤患者,采用全外显子组测序检测血浆游离DNA并作生物信息学突变分析。结果发现血浆游离DNA中存在部分癌症相关体细胞突变,但未在配对实体瘤组织中找到相同突变,作者认为血浆游离DNA突变可能不适合作为胶质瘤检测标志物。
要点
- 6例胶质瘤患者血浆游离DNA经全外显子组测序,从12,462个基因中获得33,173个突变。
- 442个基因和655个突变位点与COSMIC数据库一致。
- 仅4个突变与CGAP胶质瘤序列匹配,且与配对肿瘤组织不对应。
核心结论
- 胶质瘤患者血浆游离DNA中存在一些癌症相关体细胞突变,但未在配对实体瘤中发现相同突变,血浆游离DNA突变可能不适合作为胶质瘤检测标志物。
研究设计与样本
- 从南通大学附属医院招募6例胶质瘤患者,采集时间为2015年6月至2016年9月。
- 对血浆样本行全外显子组测序检测游离DNA,并通过生物信息学分析突变。
主要发现
- 过滤原始测序数据后,从12,462个基因中获得33,173个突变。
- 其中442个基因和655个突变位点与COSMIC数据库一致。
- 与CGAP数据库中胶质瘤突变位点比较,仅4个突变匹配,且与配对肿瘤组织不对应。
临床怎么用
- 作者认为血浆游离DNA突变可能不适合作为胶质瘤检测标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyze the plasma cell-free DNA (Cf-DNA) in glioma patients with high throughout sequencing for a novel non-invasive method for the early diagnosis and management of glioma. METHODS: Six patients with glioma were recruited from the Affiliated Hospital of Nantong University from June 2015 to September 2016. Their plasma samples were tested for Cf-DNA by whole exon sequencing and mutations were analyzed by bioinformatics. RESULTS: After filtering the raw sequencing data of Cf-DNA, 33,173 mutations were obtained from 12,462 genes of which 442 genes and 655 mutation sites were identical to that in the Catalogue of Somatic Mutations in Cancer database. However, when we compared the Cf-DNA data with the glioma mutated loci in the Cancer Genome Alta database, only 4 mutations matched with the glioma sequences in the Cancer Genome Alta and did not correspond to that of the paired-tumor tissues. CONCLUSIONS: There were some cancer-related somatic mutations in the Cf-DNA of glioma patients, but no identical mutations were found in the paired solid tumors. Therefore, plasma Cf-DNA mutations may not be a suitable marker for the detection of glioma.
引用
- Sun J, Zhou W, Mao K, et al. Examination of Plasma Cell-Free DNA of Glioma Patients by Whole Exome Sequencing. World Neurosurg. 2019. PMID: 30703591. doi:10.1016/j.wneu.2019.01.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。